6Barnes PF, Samten B, Shams H, et al. Progress in understanding the human Immune responses to Mycobacterium tuberculosis [J] . Tuberculosis ( Edinb) , 2009, 89 ( Suppll ) : S5 -S9.
7Weissler JC. Tuberculosis-immunopathogenesis and therapy [J] . Am J Med Sci, 1993, 305 (1) : 52'{)5.
8Nathan CF, Murray HW, Wiebe ME, et al. Identification of interferon?gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity[J] . J Exp Med, 1983, 158 (3): 670-689.
9OJatenoud L, Jungers P, Descanps-Lstscha B: Immunological consideration of the uremic and dialyzed patient [ J]. Kidney Int , 1994, 45 ( 44 ) : S92-S96.
10Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: A critical survey [J]. Kidney Int, 1993,43: S135- S142.
5London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kid- ney disease. Am J Kidney Dis 2002; 40:539-548 [PMID: 12200806 DOI: 10.1053/ajkd.2002.34912].
6Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacha- ryya SK, de Charro F. Economic evaluations of dialysis treatment modalities. Health Policy 2008; 86:163-180 [PMID: 18243397 DOI: 10.1016/j.healthpol.2007.12.004].
7Yu XQ, Wei JL. Kidney disease in China: recent progress and prospects. Chin Med J (Engl) 2009; 122:2048-2053 [PMID: 19781394 DOI: 10.3760/cma. j.issn.0366-6999.2009.17.016].
8Pai M, Zwerting A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update [J~. Ann Intern Med, 2008, 149(3) : 177-184.
9Madariaga MG, Jalali Z, Swindells S. Clinical utility of interferongamma assay in the diagnosis of tuberculosis [ J]. J Am Board Fam Med, 2007, 20(6) : 540-547.
10Lalvani A, Pareek M. Interferon gamma release assays: principles and practice [ J ]. Enferm Infecc Microbiolclin, 2010, 28 (4) : 245- 252.
